Syndax Pharmaceuticals (SNDX) Expected to Announce Quarterly Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $86.32 million for the quarter.

Syndax Pharmaceuticals Trading Up 2.4 %

Shares of SNDX stock opened at $16.38 on Friday. Syndax Pharmaceuticals has a 12-month low of $12.06 and a 12-month high of $25.34. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -4.51 and a beta of 0.90. The stock has a 50 day simple moving average of $13.97 and a 200-day simple moving average of $16.95.

Insider Activity at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,683 shares of company stock worth $336,087. 4.10% of the stock is owned by insiders.

Analysts Set New Price Targets

SNDX has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. The Goldman Sachs Group increased their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. Scotiabank decreased their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Finally, Citigroup raised their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).